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40-word summary 
In comparison of 2-weeks amphotericin B (AmB) + flucystosine (5FC), both 1-week AmB+5FC and 2-
weeks oral fluconazole (FLU)+5FC are cost-saving; 1-week AmB+5FC is more effective in reducing 
mortality and somewhat more costly than 2-weeks oral FLU+5FC 
 
 
Abstract  
 
Background  
Mortality from cryptoccocal meningitis remains high. The ACTA trial demonstrated that, 
compared with 2 weeks of amphotericin B (AmB) plus flucystosine (5FC), 1 week of 
AmB+5FC was associated with lower mortality, and 2 weeks of oral flucanozole (FLU) plus 
5FC was non-inferior. Here, we assess the cost-effectiveness.   
 
 
Methods  
Participants were randomised in a ratio of 2:1:1:1:1 to 2 weeks oral 5FC+FLU, 1 week 
AmB+FLU, 1 week AmB+5FC, 2 weeks AmB+FLU or 2 weeks AmB+5FC in sites in Malawi, 
Zambia, Cameroon and Tanzania. Data on individual resource use and health outcomes 
were collected from all participants. A costing study from the health care perspective was 
done in Zambia.  
 
Treatment costs were estimated using the ingredient-based approach. Cost-effectiveness 
was measured as incremental costs per life year saved . We used non-parametric 
bootstrapping of all patients by arm. Cost-effectiveness planes and acceptability curves were 
done to assess uncertainties, and a tornado sensitivity graph to examine the impact of 
individual trial parameters. 
 
Results  
Total costs per patient were US$1442 for 2 weeks oral FLU+5FC, $1763 for 1 week 
AmB+FLU, $1861 for 1 week AmB+5FC, $2125 for 2 weeks AmB+FLU, and $2285 for 2 
weeks AmB+5FC.  
 
One-week AmB+5FC was less costly and more effective than 2 weeks AmB+5FC. Two-
weeks oral FLU+5FC was less costly and as effective as 2 weeks AmB+5FC. The 
incremental cost-effectiveness ratio for one week AmB+5FC versus oral FLU+5FC was US 
$208 (95% CI: 91, 1210) per life year saved.  
 
Conclusions  
Both 1-week AmB+5FC and 2-weeks oral FLU+5FC are cost-effective treatments.  
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Background 
Mortality from cryptoccocal meningitis (CM) remains high in resource-limited settings 
[1]. The international standard induction treatment of 2 weeks amphotericin B 
deoxycholate (AmB) plus flucytosine (5FC) [2] is not available, while the alternative 
of fluconazole (FLU) monotherapy is associated with mortality of 50-60% at 10 
weeks and >70% at 1 year [3-5].  
 
The ACTA trial [6] tested new induction strategies, based on promising phase 2 data. 
Two weeks oral combination therapy with FLU plus flucytosine, and short, 1-week, 
AmB with either FLU or 5FC, were compared against the internationally 
recommended 2 weeks AmB with either FLU or 5FC, in a 2:1:1:1:1 ratio. The aim 
was to improve upon the efficacy of FLU monotherapy with regimens that, unlike 2 
weeks AmB, could be more readily sustained in resource-limited settings. The trial 
showed that 1 week AmB+5FC was associated with lower mortality and the oral 
combination was non-inferior compared with the recommended 2 weeks AmB+5FC.  
 
Given the scarcity of resources, detailed evidence on the health care costs of 
treatment and on associated health impact are essential to inform policy decisions. 
AmB is intravenous and requires hospitalization and stringent laboratory monitoring, 
FLU is oral and available through donation programmes or as low-cost, generic 
manufacture. The current availability of 5FC is very limited.  
 
There are very few detailed studies of the costs of alternative CM treatments 
available to date. Therefore, within the ACTA trial, we conducted a comparative cost-
effectiveness study of the 5 regimens tested, in order to support and guide policy 
decisions.  
 
Methods 
The ACTA trial [6] was an open label, phase 3, randomised non-inferiority, multi-centre trial, 
in which patients with HIV-associated cryptococcal meningitis from 9 African centres in four 
countries (Malawi, Zambia, Tanzania and Cameroon) were enrolled between January 2013 
and November 2016. Participants were first randomised to three strategies: oral combination 
regimen, 1 week AmB, and standard 2 weeks AmB and those in the AmB arms were further 
randomised to 5FC or FLU in a 1:1 ratio, as the partner drug treatment. This resulted in 5 
arms i) oral 5FC+FLU 2 weeks, ii) one week AmB+FLU, iii) one week AmB+5FC, iv) 2 weeks 
AmB+FLU and v) 2 weeks AmB+5FC in a ratio of 2:1:1:1:1.  
 
A full economic costing and cost-effectiveness analysis of the cryptococcal meningitis 
treatments was done, by the CHEERS appraisal guidelines [7], from the health care 
perspective. Resource use data were collected using an ingredients-based approach [8, 9]. 
The data on individual resource use and health outcomes, including trial-related 
complications and treatment of complications, were collected from all participants onto case-
report forms (CRFs). A detailed costing study was done in the Zambian hospital (See Table 
1 and Supplementary Material). CM -specific and overhead costs, including costs of 
admissions and laboratory tests, were collated from the hospital’s financial and utilisation 
documents. The treatment-related utilisation data were collated from the CRFs. These were 
collected on length of stay in hospital, types of diagnostic tests, medical supplies and drugs 
used. Discussions were held with relevant hospital staff for data triangulation. The ACTA 
study team were consulted on the trial-related expenditure and resource utilization data in 
relation to complications. Where unit costs were not available in the expenditure records, 
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local market prices were used.  
 
A time-and-motion study was conducted to inform the monetary valuation for care received 
provided by health staff at the bed-side. It collected information on the type and intensity of 
care received by a purposive sample of 59  trial participants. Each participant was observed 
for two consecutive days. Findings on time spent on patient care were combined with 
salaries (including all financial benefits) to estimate total staff costs spent on caring for CM 
patients. (See Table 1). We collected data on health care resource and unit prices, adjusted 
to 2015 US$ price level and included the effects of bulk purchasing, and delivery / shipping 
charges. An average annual exchange rate for the trial baseline year and subsequent 
inflation corrections were used in the currency conversion and inflation correction. 
 
Aggregated hospital expenditures were allocated proportionally to relevant institutional units 
and departments. This was complemented with observations to establish costs allocation 
factors (e.g. floor surface, number of beds, number of medical staff), in particular in the 
allocation of overhead costs. These additional costs were disaggregated and summarized in 
costs per bed-day, CM treatment-specific costs and laboratory test costs according to 
recurrent and capital costs,and non-specific costs of additional use of antibiotics in relation to 
complications. Recurrent cost items were considered to be goods/services with a life span of 
less than one year whereas capital costs were defined as costs which were incurred to 
purchase good/services which last for more than one year. Capital costs were few and 
limited to those related to diagnostics and were annualised over their economic life (informed 
by the Zambian hospital’s accounting documents) using a discount rate of 3% [9, 10]. The 
analysis included institutional and department overheads including for hospital 
administration, drug and other supply chain management. A detailed listing is given in Table 
1 while a more detailed description of the cost component is presented in the Supplementary 
Material.  
 
The health outcome included in the cost-effectiveness analysis is life year saved, based on 
the age of the patients saved from dying. Here we multiplied the additional deaths prevented 
with the observed CD4-specific weighted life expectancy [11].  The average life expectancy 
of the additional survivors was estimated conservatively at 18 years [11]. We did not make a 
long-term quality-of-life adjustment as the mortality reduction is substantial and defined as 
the main outcome of the trial. Quality-of-life outcomes after CM meningitis in these patient 
groups are lacking. We used a differential discount rate for health care costs (3% per 
international standard) and life years gained (0% as given in the literature) [12, 13].  
 
Statistical analysis  
Total cost – that is observed use of resources multiplied by a specific unit price, increased 
for specific overhead costs - was adjusted using a Kaplan-Meier average estimator to 
account for censoring from death or lost to follow-up [14].  Individual patient costs were 
calculated and non-parametric bootstrapping was used to draw a stable sample (defined as 
the percentage change in standard deviation between two subsequent samples [15]) from 
patient records by treatment arm to allow for the skewed distribution of costs and the 
correlation between costs and effectiveness [16]. 
 
The 95% confidence intervals for the total cost per patient  and probability of death were 
calculated using bias-corrected percentile acceleration method [15].  The five ACTA 
treatments were ranked by their increasing cost and we ruled out strategies that were less 
effective and more costly than the comparator (less economically attractive or dominated in 
economic terms) and strategies that were less effective and had a higher incremental cost-
effectiveness ratio (extended dominance). Of the remaining strategies, incremental cost-
effectiveness ratios were calculated for each strategy relative to standard treatment and the 
next best alternative. 
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Costs per life year saved were estimated  by dividing mean incremental costs by mean 
number of life years saved. Cost-effectiveness planes and an acceptability curve were used 
to show the uncertainties around incremental cost-effectiveness ratios. A series of (one-way) 
sensitivity analyses were done varying one parameter at a time to address uncertainty in the 
data inputs (including, especially, the observed uncertainty range around patient-level 
resources use shown in Table 2 and the uncertainties in the observed mortality rate and 
observed range of life expectancy(12.8 to 40.81) [17] to compute the uncertainties in 
incremental cost-effectiveness ratios [18]. Here, the parameters in the standard treatment 
arm were kept constant. The effects of the top-ranking individual parameters are presented 
by a tornado sensitivity graph. 
 
Ethics  
 
The trial protocol and data collection was approved by London School of Hygiene and 
Tropical Medicine Research Ethics Committee and by the national ethics and regulatory 
bodies in each country. Written informed consent was obtained from all participants or, in the 
case of those with altered mental status, from the next of kin (the participants were re-
consented on recovery).  
 
 
Results 
 
The ACTA trial analysis comprised 678 eligible participants.[6]  Only 4 patients were lost to 
follow-up. Mortality at 10 weeks (Table 3) was 251 (37%) overall, and was lowest for one 
week AmB + 5FC (24%, 95% CI 16, 31) [6].   
 
Resource use, costs and health outcomes 
 
The unit prices are shown in Table 1. The cost per bed day was 2015 US$ 48. This excludes 
CM treatment-specific costs and laboratory test costs. Detailed resource use by trial arm is 
presented in Table 2. The differences between the trial arms in resource use were largely 
driven by the component drugs and complication-related resource use. Thus, blood 
transfusions and potassium and magnesium supplementation were highest for participants in 
the 2 week AmB arms and lowest for the oral 5FC+FLU combination. The duration of 
hospitalisation was largely similar between the trial arms as this was protocol-driven. 
Participants were asked to remain in hospital as inpatients for at least 14 days for trial safety 
monitoring.  
 
Mean per patient total costs were lowest for the oral 5FC+FLU combination (US $1442) and 
highest for 2 AmB + 5FC (US$ 2285) (Table 3). The total cost of bed-days per patient (both 
hospitalisation and re-hospitalisation) was the major cost component, from 36% for 2 weeks 
AmB+FLU to 56% of costs for the oral arm. More than 75% of the costs were incurred during 
the first two weeks.  
 
Cost effectiveness and uncertainty  
 
1 week AmB+5FC was less costly and more effective than (i.e. dominated) 2 weeks 
AmB+5FC (Table 3, Figure 1). The 2 weeks oral 5FC+FLU combination was also less costly 
than 2 weeks AmB+5FC but the reduction in mortality was marginal (Table 3 and Figure 1).  
Both 2 weeks AmB+FLU and 1 week AmB+FLU were cost-saving compared with 2 weeks 
AmB+5FC, but these treatments were associated with increased mortality (Table 3 and 
Figure 1).  
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Therefore, 1-week AmB+5FC and the 2 weeks oral combination were the two most attractive 
induction treatments. Figure 2 shows the uncertainty around the health service cost savings 
in relation to the number of lives saved, in scatter plots of the cost-effectiveness plane. In 
comparison to 2 weeks AmB+5FC, 2 weeks oral 5FC+FLU combination is robustly cost 
saving but the health gain is much less certain. The 1 week AmB+ 5FC arm shows a robust 
reduction in both cost and deaths. Finally, in a head-to-head comparision (Table 3, right 
side) 1-week AmB+ 5FC shows a robust health gain at some additional cost compared with 
the oral 5FC+FLU regimen (US$ 208 (95% CI: 91-1210, per life year gained).  
 
Figure 2 shows the probability (y-axis) that 1 week AmB+5FC is cost-effective when 
compared with 2 weeks oral 5FC+FLU at the complete full range of willingness to pay 
thresholds (x-axis). The probability of being cost-effective exceeds 90% at a threshold of 
US$490 and is around 80% at a threshold of US$330 per life year saved.  
 
Multi-variate sensitivity analysis 
 
We varied all the resource parameters (Table 2) and the health outcomes (Table 3) in an 
empirical multi-variate sensitivity analysis (Figure 3). The top five drivers of the incremental 
cost-effectiveness ratio were mortality rate, life expectancy, number of bed days 
hospitalised, re-hospitalization days and total AmB dosage. The latter and all other 
parameters did not substantially influence the incremental cost-effectiveness results. The 
tornado graph in Figure 3 shows the effect of varying the value for each important parameter 
on the incremental cost-effectiveness ratio of 1 week AmB+5FC compared with the oral 
regimen, given the uncertainty ranges in the individual parameters in probabilistic analyses.. 
If the mortality for 1 week AmB+5FC was varied from 16% to 31% (i.e. the lower and upper 
95% CI of the mortality estimate), then the incremental cost-effectiveness ratio would vary 
between $121 and $638, assuming other parameters were constant.  
 
 
Discussion 
This study shows that 1-week AmB+5FC and oral FLU+5FC were the most cost-effective 
regimens and both are suitable to replace 2-weeks AmB+5FC as the preferred regimens in 
many settings. In comparison with 2 weeks AmB+5FC, both regimens were less costly and 
one week AmB+5FC led to substantial health gains while the oral combination was at least 
as effective.  
 
 
The findings for one 1-week AmB+5FC were very robust. Even when the mortality of 1-week 
AmB+5FC was varied to the upper 95%CI limit of 31%, 1-week AmB+5FC still dominated 2 
weeks AmB+5FC. In an arm-to-arm comparison, the estimated incremental cost 
effectiveness ratio for 1-week AmB+5FC versus oral 5FC+FLU combination was $208 per 
life year saved. The 1-week AmB+5FC combination represents a cost-effective option in 
clinical settings in Africa where AmB can be given and monitored. Importantly however, oral 
fluconazole and flucytosine provides a cost-effective option for more severely resource-
limited settings where AmB therapy is not possible, that is as effective as the current 
international standard of care and reduces service costs. The findings re-emphasise the 
absolute necessity of current international efforts to secure immediate and wide access to 
flucytosine.  
 
This is the first large study based on the collection of protocol-driven patient-level resource 
use data across different African countries. These data were supplemented with medical and 
nursing staff time information and an empirical costing study in the Zambian public hospital 
site. Here, as in many other sub-Saharan African countries, costs data are not included in 
routine health service data collection. Therefore, as part of ACTA, we undertook substantial 
efforts to obtain reliable, consistent and accurate data on components of the service cost per 
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bed day, the main driver of total costs per patient. The resulting cost per bed day was 
relatively high (US$ 48) – it reflected the real-life local cost of intensive treatment  and local 
procurement, and excluded CM treatment-specific costs and specific laboratory test costs. 
 
In a prior study to compare the cost-effectiveness of alternative regimens, Rajasingham et al 
concluded that 1-week AMB plus fluconazole would likely be much more cost effective than 
2-week AmB courses [11]. A limitation acknowledged by the authors was that the efficacy 
component was based on pooled mortality data available at that time across small, often 
non-comparative studies, and from different settings. Our service costs and resource use 
data are linked to the largest trial to date. The results confirm the economic attractiveness of 
1-week AmB in relation to 2-weeks AmB, in terms of cost savings and higher effectiveness, 
but only in combination with 5FC as the partner drug, and also demonstrate the 
attractiveness of the combination of the two oral drugs, fluconazole and 5FC. The 1-week 
course with AmB comes at an additional price compared wth oral FLU+5FC, that may be 
affordable in many SSA country settings, and compares well with a range of other clinical 
interventions, including  prevention of mother to child HIV transmission, MDR TB treatment, 
and intrapartum care [19] [20] [21]. 
 
The cost-effectiveness advantage of 1-week AmB+5FC and oral FLU+5FC over 2-week 
AmB regimens is underestimated in our analysis. We measured actual durations of 
hospitalisation of the ACTA trial participants, which for trial safety monitoring reasons, 
required participants to be hospitalised under close observation for the first 2 weeks. In real-
life implementation, the duration of hospitalisation for patients on the oral or 1-week AmB 
regimens would, in all likelihood, be lower and the cost of these regimens would decrease in 
relation to 2-week AmB regimens which require a minimum duration of hospitalisation of 14 
days. If we included all societal cost consequences, including those at household level, the 
total societal cost savings of the oral or 1-week AmB regimens over 2-week AmB regimens 
would increase further, as travel and loss of household productivity in relation to 
hospitalisation would be reduced, as well as the out-of pocket patient-related cost born by 
carers.  
 
In an explorative scenario, we subtracted the cost of the second week’s admission from the 
total for any patient discharged on day 14 or earlier who was on oral treatment or on 1-week 
AmB+5FC (using the original trial data).  This short hospital stay scenario results in a total 
per patient cost of US$ 767(95% CI: 722, 841) for the oral arm and US$ 1161 (95% CI: 
1114, 1225) for 1 week AmB. These costs are about half those of per protocol hospital stays 
for patients on these arms and substantially lower than the costs of 2 weeks AmB+ 5FC 
($2285), making the oral and 1 week AmB+5FC even more attractive. Importantly, the 
incremental cost effectiveness of 1-week AmB+5FC versus the oral combination would not 
be altered by this consideration since all CM patients require some period of hospitalisation 
for optimal care, including measurement and management of raised cerebrospinal fluid 
pressure.  
 
The study provides further strong support for the recently updated WHO guidelines for the 
treatment of HIV-associated cryptococcal meningitis that recommend 1-week AmB+5FC and 
oral FLU+5FC as the first and second preferred regimens. Flucytosine needs to be made 
available widely to reduce cryptococcal-associated mortality 
 
Supplementary Data 
Supplementary materials are available at Clinical Infectious Diseases online. Consisting of 
data provided by the authors to benefit the reader, the posted materials are not copyedited 
and are the sole responsibility of the authors, so questions or comments should be 
addressed to the corresponding author.  
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Table 1. Unit prices (US $ in 2015) by resource item and source of unit price. 
Resource Item Supplies** Staff Capital Total Source 
Costs per bed-day 9.45 37.06 1.14 47.64 
 
Costing study 
Lumber puncture, per time 0.94 7.49 1.14 9.57 Costing study 
Bio-chemistry, per test     
 
  Total Bilirubin 1.9 2.63 0.27 4.8 
Costing study 
  C-reactive protein  5.77 2.63 0.27 8.67 Costing study 
  Alanine transaminase   4.04 2.63 0.27 6.94 Costing study 
  Magnesium  2.05 2.63 0.27 4.95 Costing study 
     
 
      
  Urea 1.94 2.63 0.27 4.84 Costing study 
  Creatinine 1.83 2.63 0.27 4.73 Costing study 
  Proteinuria 1.96 2.63 0.27 4.86 
Costing study 
Microbiology, per test     
 
  Urine culture - negative 1.5 5.92 0.43 7.84 Costing study 
  Urine culture - positive 2.08 8.65 0.43 11.16 Costing study 
  Blood culture - negative 1.03 6.17 0.55 7.74 Costing study 
  Blood culture - positive 3.39 9.79 0.55 13.73 Costing study 
  Sputum culture - negative 2.13 4.4 0.45 6.98 Costing study 
  Sputum culture - positive 4.04 8.02 0.45 12.5 Costing study 
  CSF - negative 9.06 13.15 0.46 22.66 Costing study 
  CSF - positive 9.98 15.88 0.46 26.31 Costing study 
Full Blood Count, per test 32.28 4.04 0.28 36.59 Costing study 
CD4 Count, per test 7.38 9.04 1.37 17.79 
Costing study 
CM-specific treatment      
 11
  Trial drug   
 
  
    Fluconazole per 1200mg 0.55 0.55 Provider 
   flucytosine per 500mg  1.53 1.53 
Provider 
   Amphotericin B per 1 mg  1.18 1.18 
Provider 
   Antibiotics   
 
     Flucloxacillin per day  0.2 0.2 
Pharmacy 
     Gentamicin per day 0.26 0.26 Pharmacy 
     Ceftriaxone per ampoule 0.52 0.52 Pharmacy 
     Amoxicillin/Ampicillin per ampoule 0.066 0.066 Pharmacy 
     Doxycycline per day 0.038 0.038 
Pharmacy 
     Erythromycin per day 0.144 0.144 Pharmacy 
     Ciprofloxacin per day 0.10 0.10 Pharmacy 
Other intervention    
     Potassium 0.105 0.105 Pharmacy 
     Magnesium 1.45 1.45 Pharmacy 
Blood transfusion per unit 35  35 Hospital department 
  Potassium  2.90  2.90 Costing study 
  Sodium  2.90  2.90 Costing study 
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Table 2. Mean (standard deviation) resource use per patient by trial arm, over 10 weeks trial period.  
Service use item Service use item 2 weeks oral FLU and 5FC 1 week AmB+FLU  1 week AmB+5FC 2  weeks AmB+FLU  2 weeks AmB+5FC 
Hospitalization Days  17.33(15.29) 17.14(18.04) 17.99(15.06) 16.09(12.27) 19.31(18.31) 
Re-hospitalization Days  2.02(5.23) 2.14(6.31) 0.88(2.72) 1.77(5.48) 1.38(4.10) 
CM-specific treatment       
 Trial drug        
   Fluconazole Tablet (200 mg) 187.96(123.83) 147.18(130.65) 161.50(148.25) 170.68(125.26) 120.37(159.31) 
   flucytosine  Tablet (500mg) 131(56) 0.00(0.00) 74(23) 0.00(0.00) 131(59) 
   Amphotericin B (AmB)  Vial (50mg) 0.00(0.00) 6.50(2.60) 7.35(2.12) 12.71(5.53) 13.07(5.94) 
Antibiotics       
   Flucloxacillin  times  0.03(0.17) 0.06(0.24) 0.05(0.23) 0.13(0.34) 0.09(0.28) 
   Gentamicin  times  0.02(0.13) 0.00(0.00) 0.01(0.09) 0.02(0.13) 0.03(0.18) 
  Ceftriaxone  Ampoule 0.62(0.49) 0.65(0.48) 0.58(0.50) 0.60(0.49) 0.66(0.48) 
  Amoxicillin/Ampicillin  Ampoule 0.06(0.24) 0.06(0.24) 0.11(0.31) 0.07(0.26) 0.04(0.20) 
  Doxycycline  times  0.01(0.09) 0.05(0.21) 0.00(0.00) 0.04(0.18) 0.01(0.09) 
  Erythromycin  times  0.00(0.00) 0.01(0.09) 0.01(0.09) 0.01(0.09) 0.00(0.00) 
  Ciprofloxacin  times  0.05(0.22) 0.03(0.16) 0.04(0.21) 0.04(0.21) 0.01(0.09) 
Other intervention       
     Potassium  days  0.00(0.00) 6.05(2.20) 6.72(1.43) 11.71(4.41) 11.83(4.62) 
     Magnesium days  0.00(0.00) 6.05(2.20) 6.72(1.43) 11.71(4.41) 11.83(4.62) 
Blood transfusion Units 0.12(0.52) 0.23(0.66) 0.15(0.57) 0.31(0.73) 0.37(0.86) 
Lumbar puncture times  3.13(1.84) 2.62(1.07) 3.26(1.39) 2.93(1.59) 2.98(1.44) 
Bio-chemistry       
  Total Bilirubin times  1.69(2.95) 1.57(2.77) 1.74(2.99) 1.44(2.79) 1.63(2.94) 
  CRP times  0.06(0.31) 0.09(0.39) 0.04(0.21) 0.11(0.42) 0.10(0.41) 
  ALT times  3.48(2.09) 3.04(1.73) 3.69(2.00) 3.66(2.32) 3.40(1.99) 
  Magnesium (Mg) times  0.19(0.73) 0.20(0.75) 0.20(0.67) 0.16(0.66) 0.22(0.81) 
  Potassium (K) times  7.00(3.15) 6.23(3.21) 7.22(2.35) 7.07(3.12) 6.83(3.21) 
  Sodium (Na) times  7.02(3.09) 6.25(3.21) 7.27(2.41) 7.12(3.14) 6.90(3.23) 
  Urea times  6.99(3.12) 6.22(3.14) 7.19(2.44) 7.04(3.07) 6.79(3.12) 
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  Creatinine times  7.15(3.17) 6.32(3.32) 7.39(2.45) 7.18(3.12) 6.98(3.29) 
  Proteinuria times  7.64(3.48) 6.82(3.80) 7.82(2.71) 7.87(3.63) 7.47(3.65) 
Full Blood Count times  4.62(2.39) 4.26(2.62) 4.68(1.96) 4.69(2.41) 4.63(2.60) 
CD4 Count times  0.97(0.37) 1.01(0.37) 0.93(0.29) 0.97(0.45) 0.98(0.30) 
Microbiology *       
  Urine culture - 
negative times  0.08(0.34) 0.07(0.32) 0.04(0.19) 0.11(0.36) 0.09(0.45) 
  Urine culture - positive times  0.05(0.26) 0.04(0.23) 0.02(0.13) 0.04(0.18) 0.02(0.13) 
  Blood culture - 
negative times  0.12(0.36) 0.08(0.27) 0.10(0.33) 0.12(0.44) 0.10(0.40) 
  Blood culture - positive times  0.07(0.27) 0.09(0.35) 0.04(0.19) 0.13(0.45) 0.04(0.24) 
  Sputum culture - 
negative times  0.00(0.00) 0.00(0.00) 0.01(0.09) 0.00(0.00) 0.00(0.00) 
  Sputum culture - 
positive times  0.07(0.27) 0.09(0.35) 0.07(0.29) 0.06(0.28) 0.08(0.27) 
  CSF - negative times  0.64(0.88) 0.77(0.99) 1.27(1.04) 0.75(0.84) 1.34(1.21) 
  CSF - positive times  2.44(1.88) 1.83(1.14) 1.95(1.39) 2.17(1.63) 1.56(1.02) 
 
*  Negative cultures are less costly than positive cultures.   
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Table 3. Probabilistic cost-effectiveness analyses comparing the trial arms in terms of mean total health care costs and death rate (%). 
  
Total cost per patient and death rate (%) per arm 
Incremental comparison of 
1 week of AmB+5FC versus 2 weeks of FLU+5FC 
ACTA treatment 
arms Mean total costs Deaths (%) 
Incremental costs 
per patient 
Incremental 
death rate (%)  
Incremental 
costs per life year saved 
2 week Oral FLU+5FC 1442 (1336 -1565) 35(28-41) Reference Reference Reference 
1 week AmB+FLU 1763 (1567 -1979) 49(39-58) - - - 
1 week AmB+5FC 1861 (1724 -2033) 24(16-31) 419 (236, 619) 11 (0.6, 21) 208 (91, 1210) 
2  weeks AmB+FLU 2125 (1946 -2313) 41(32-49) - - - 
2 week AmB+5FC 
(Comparator) 2285 (2070 -2525) 38(29-46) - - - 
  
 Note: Two weeks of oral treatment and 1 week AmB+5FC show lower costs and better health outcomes than the other treatment combinations (i.e. cost 
less and averted more deaths).  In economics terms: these two treatments ‘dominate’ the other options. Incremental cost-effectiveness is calculated for 
these remaining favourable options on the right half of the table. Average estimated life expectancy is 18 years as reported in Rajasingham’ study[11]. The 
numbers in parenthesis are estimates of the 95% confidence intervals as estimated by boot-strapping. Abbreviation: AmB - amphotericin B; FLU- 
Fluconazole; 5FC- flucytosine 
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LEGENDS TO FIGURES 
Figure 1. Cost-effectiveness planes after bootstrap iterations (1000 selected at random are shown) to present incremental costs  and  death prevented (%) 
after the 10 week trial period, for Oral 5FC+FLU versus 2 weeks AmB+5FC (A), 1 week AmB+5FC versus 2 weeks AmB+5FC (B) and 1 week AmB+5FC versus 
Oral FLU+5FC (C).  Ellipses show 95% confidence intervals. Red dots indicate the means for both axes.  Abbreviation:  AmB - amphotericin B; FLU- 
Fluconazole; 5FC- flucytosine. 
 
  
Figure 2. Cumulative probability of the incremental cost-effectiveness ratio being below different thresholds for the comparison of 1-week AmB+5FC versus 
oral FLU+5FC combination. 
 
Figure 3. Tornado diagram of incremental cost-eff effectiveness ratio (ICER) for 1-week AmB+5FC vs. oral combination for major components.  
All other resource parameters were not influential. NB. The analyses use the 95% of the input distribution for resource use and health 
outcomes parameters to eliminate extreme outliers. The input ranges are based on the overall results from bootstrap methods described in the 
methods section, using individual participant data. Life expectancy input data are from a comparable cohort[11, 17] Abbreviations:  AmB - 
amphotericin B; 5FC- flucytosine; ICER- incremental cost-eff effectiveness ratio.
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